| PRECLINICAL | evidence | An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | No evidence that tirzepatide can worsen diabetic retinopathy. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter]. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Reassessing retinopathy risk with tirzepatide therapy. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database. | Tirzepatide | Glycemic control | 2025-12-01 |
| PRECLINICAL | evidence | Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus. | Tirzepatide | Glycemic control | 2025-12-01 |
| PRECLINICAL | evidence | Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Optimizing GLP-1 therapies for obesity and diabetes management. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report. | Mounjaro | — | 2025-12-01 |
| PRECLINICAL | evidence | Real-world effects of incretin-based Obesity medications on body composition. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape. | Mounjaro | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation. | Mounjaro | — | 2025-12-01 |
| PRECLINICAL | evidence | Tirzepatide affects NAc activity and food preoccupation. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA). | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Cardiovascular efficacy of tirzepatide: what real-world evidence promises. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss. | Mounjaro | — | 2025-12-01 |
| PRECLINICAL | evidence | Injectable drugs for weight management. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis. | Tirzepatide | Weight & fat loss · n = 6641 | 2025-12-01 |
| PRECLINICAL | evidence | Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report. | Tirzepatide | — | 2025-12-01 |
| PRECLINICAL | evidence | Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment. | Tirzepatide | Weight & fat loss | 2025-12-01 |
| PRECLINICAL | evidence | Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists. | Tirzepatide | Lipid & cardiovascular markers | 2025-12-01 |
| PRECLINICAL | evidence | Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures. | Mounjaro | — | 2025-12-01 |
| PRECLINICAL | evidence | Exploring Adults' Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study. | Tirzepatide | — | 2025-11-28 |
| PRECLINICAL | evidence | The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials. | Tirzepatide | — | 2025-11-27 |
| PRECLINICAL | evidence | Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective? | Tirzepatide | Weight & fat loss | 2025-11-27 |
| PRECLINICAL | evidence | Noninsulin drugs for type 2 diabetes. | Mounjaro | — | 2025-11-24 |
| PRECLINICAL | evidence | Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. | Mounjaro | — | 2025-11-24 |
| PRECLINICAL | evidence | Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. | Tirzepatide | — | 2025-11-23 |
| PRECLINICAL | evidence | [Not Available]. | Tirzepatide | — | 2025-11-19 |
| PRECLINICAL | evidence | Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis. | Tirzepatide | — | 2025-11-19 |
| PRECLINICAL | evidence | Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients. | Mounjaro | — | 2025-11-15 |
| PRECLINICAL | evidence | Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity. | Tirzepatide | — | 2025-11-15 |
| PRECLINICAL | evidence | Research Design Concerns in a TriNetX Study of Tirzepatide and Heart Failure Prevention in Obese Patients. | Tirzepatide | — | 2025-11-12 |
| PRECLINICAL | evidence | [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea]. | Tirzepatide | — | 2025-11-12 |